ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)

Completed

Conditions: Work Productivity
Psoriatic Arthritis

First Posted Date: 2014-01-07

Last Posted Date: 2017-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 120

Registration Number: NCT02028169

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/r/ABT-267
Drug: Placebo

First Posted Date: 2013-12-30

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 363

Registration Number: NCT02023099

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: ABT-450/r/ABT-267
Drug: Ribavirin

First Posted Date: 2013-12-30

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 171

Registration Number: NCT02023112

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis
Nail Psoriasis

Interventions: Biological: Adalimumab
Other: Placebo

First Posted Date: 2013-12-20

Last Posted Date: 2017-05-30

Lead Sponsor: AbbVie

Target Recruit Count: 217

Registration Number: NCT02016482

Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®

Completed

Conditions: Respiratory Syncytial Virus Infection

First Posted Date: 2013-12-20

Last Posted Date: 2017-03-20

Lead Sponsor: AbbVie

Target Recruit Count: 312

Registration Number: NCT02016690

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab
Biological: Placebo for adalimumab

First Posted Date: 2013-12-19

Last Posted Date: 2018-05-30

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT02015793

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Phase 1

Completed

Conditions: Colon Cancer
Gastric Cancer
Lung Cancer
Breast Cancer
Ovarian Cancer
Solid Tumors

Interventions: Drug: Placebo
Drug: Veliparib (ABT-888)

First Posted Date: 2013-12-12

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 45

Registration Number: NCT02009631

Locations: 🇳🇱
Site Reference ID/Investigator# 117320, Groningn, Netherlands
🇺🇸
Site Reference ID/Investigator# 116015, Scottsdale, Arizona, United States
🇳🇱
Site Reference ID/Investigator# 117336, Maastricht, Netherlands

and more 2 locations

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Phase 2

Completed

Conditions: Compensated Cirrhosis
Chronic Hepatitis C
Hepatitis C Virus

Interventions: Drug: ABT-493
Drug: ABT-530
Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin (RBV)

First Posted Date: 2013-11-26

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 89

Registration Number: NCT01995071

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
AML
Acute Myeloid Leukemia

Interventions: Drug: ABT-199

First Posted Date: 2013-11-26

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 32

Registration Number: NCT01994837

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: ABT-199
Drug: Ketoconazole

First Posted Date: 2013-10-25

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01969669

Locations: 🇺🇸
Site Reference ID/Investigator# 97498, Tucson, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 92593, Lebanon, New Hampshire, United States
🇺🇸
Site Reference ID/Investigator# 101415, Hackensack, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy